Asthma Endotyping Assay for Precise Antibody Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments are often ineffective and costly due to the heterogeneity of the disease, leading to significant healthcare costs and ethical concerns regarding the use of expensive therapies without desired clinical effects.
Innovation Solution
A combinatory asthma endotyping assay that determines the gene expression levels of specific cytokines and receptors in patient samples to identify precise asthma subtypes, enabling personalized therapy choices and optimizing treatment responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If immunotherapy is prescribed for asthma treatment, then treatment options increase, but healthcare costs increase significantly
Solution Approach 1:
The patent applies preliminary action by performing asthma subtyping diagnosis before initiating immunotherapy treatment. The combinatory assay evaluates multiple genes (IL-1B, IL-6, IFN-γ, IL-2, IL-4, IL-5, IL-13, IL-21, IL-25, IL-33, IL-37, TSLP, GATA-3, CCR3, IL-17A, IL-22, IL-23, GM-CSF) to classify patients into specific asthma subtypes (eosinophilic, neutrophilic, mixed, etc.) before treatment, enabling selective prescription of appropriate immunotherapies and avoiding ineffective treatments.
Solution Approach 2:
The patent changes the diagnostic parameter from traditional clinical criteria to molecular gene expression profiling. By measuring the expression levels of multiple cytokine and receptor genes in patient samples, the system transforms asthma diagnosis into a precision medicine approach that identifies specific molecular signatures associated with different asthma subtypes, thereby enabling personalized treatment selection.
2Reliability
If multiple antibody therapies are made available, then treatment effectiveness may improve, but treatment costs increase
Solution Approach 1:
The patent implements feedback through a diagnostic system that provides actionable information about a patient's asthma subtype before treatment initiation. The combinatory assay generates a molecular profile that feeds back to guide treatment selection, ensuring that expensive antibody therapies are prescribed only when molecular markers indicate likely effectiveness, thereby optimizing the reliability of treatment outcomes while controlling costs.
Solution Approach 2:
The patent applies local quality by tailoring treatment approaches to specific local characteristics of each patient's asthma subtype. Instead of applying a one-size-fits-all treatment strategy, the system identifies specific molecular signatures (e.g., high IL-5 expression suggesting eosinophilic asthma) and customizes therapy accordingly, ensuring that resources are allocated to treatments most likely to work for each individual patient.
3Ease of operation
If asthma treatment is based on practical knowledge only, then treatment decisions are made quickly, but treatment precision is insufficient
Solution Approach 1:
The patent performs preliminary molecular characterization of asthma subtypes before treatment decision-making. By pre-classifying patients into distinct molecular subtypes through gene expression profiling, the system prepares precise treatment recommendations in advance, combining rapid classification algorithms with molecular data to achieve both speed and precision in treatment decisions.
Data Source
AI summary
The present disclosure relates to methods of diagnosing an asthma subtype in a patient using a combinatory asthma endotyping assay. Furthermore, the disclosure relates to a kit and a marker panel for use in these methods.